Hyperthermic intraperitoneal chemotherapy does not increase risk of major complication or failure to rescue in cytoreductive surgery.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Combined Modality Therapy
Cytoreduction Surgical Procedures
/ adverse effects
Humans
Hyperthermia, Induced
/ adverse effects
Hyperthermic Intraperitoneal Chemotherapy
/ adverse effects
Peritoneal Neoplasms
/ surgery
Retrospective Studies
Sepsis
Survival Rate
outcomes
peritoneal surface malignancy
surgery
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
revised:
27
04
2022
received:
04
01
2022
accepted:
07
05
2022
pubmed:
8
6
2022
medline:
13
8
2022
entrez:
7
6
2022
Statut:
ppublish
Résumé
Failure to rescue (FTR) is defined as death after a major complication. We evaluated FTR after cytoreductive surgery (CRS) with and without hyperthermic intraperitoneal chemotherapy (HIPEC). The ACS NSQIP database 2005-2018 was reviewed for all cases of CRS. Propensity score matching was used to compare outcomes between those undergoing CRS alone and those undergoing CRS/HIPEC. Patients were matched on age, sex, ascites, diabetes, hypertension and resection of liver, pancreas, colon/rectum, diaphragm, stomach, small bowel, and/or spleen. Thirty nine thousand one hundred and twenty-six patients underwent CRS; 38,387 underwent CRS alone; 739 underwent CRS/HIPEC. After matching there were 726 patients in each arm. Patients undergoing CRS/HIPEC had higher risk of reintubation (25 [3.4%] vs. 13 [1.8%] p = 0.049), urinary tract infection UTI (44 [6.1%] vs. 25 [3.4%] p = 0.019) and sepsis (73 [10.1%] vs. 44 [6.1%] p = 0.005). Patients in the CRS arm required more transfusions (229 [31.5%] vs. 176 [24.2%] p = 0.002). There was no significant difference in FTR between the CRS and CRS/HIPEC groups (11 [4.0%] vs. 6 [2.3%] p = 0.258), nor in the pooled incidence of major complications (275 [37.9%] vs. 262 [36.1%] p = 0.48). CRS/HIPEC is associated with increased rates of reintubation, UTI, and sepsis while CRS alone was associated with increased transfusion. However, the addition HIPEC to CRS did not increase the risk of pooled major complication or FTR.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
781-786Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Jafari MD, Halabi WJ, Stamos MJ, et al. Intraperitoneal Chemotherapy Analysis of the American College of Surgeons National Surgical Quality Improvement Program. JAMA Surg. 2014;149(2):170-175.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284-3292.
Levine EA, Stewart JH, 4th, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204(5):943-953.
Benhaim L, Faron M, Gelli M, et al. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. Surg Oncol. 2019;29:78-83.
Quenet F, Elias D, Roca L. Cytoreductive surgery plus hyperthermic intraoperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastasis (PRODIGE 7): a multicentre, randomised, open-lable, phase 3 trial. Lancet Oncol. 2021;22(2):256-266.
Noiret B, Clement G, Lenne X, et al. Randomized trial of cytoreduction and hyperthermic intraoperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737-3743.
Liu JB, Schuitevoerder D, Vining CC, Berger Y, Turaga KK, Eng OS. Failure to rescue following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2017;214:209-215.
Khuri SF. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. Ann Surg. 2020;138:837-843.
Khuri S. The NSQIP: a new frontier in surgery. J Am Coll Surg. 2005;138:837-843.
Holte K, Foss NB, Andersen J, et al. The patient safety in surgery study: background, study design, and patient populations. J Am Coll Surg. 2007;204:1089-1102.
Hendrix RJ, Damle A, Williams C, et al. Liberal or restrictive fluid administration in fast-track colonic surgery: a randomized, double-blind study. Br J Anaesth. 2008;100(2):284-496.
Saxena A, Yan TD, Chua TC, et al. Restrictive intraoperative fluid therapy is associated with decreased morbidity and length of stay following hyperthermic intraopertioneal chemoperfusion. Ann Surg Onc. 2019;26:490-496.
Bell T, O'Grady N. Prevention of central line-associated bloodstream infections. Infect Dis Con North Am. 2017;31(3):551-559.
Verwaal VJ, van Ruth S, de Bree E, et al. Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Support Care Cancer. 2020;28(6):2745-2752.
Bell T, O'Grady NP. Risk factors for massive blood transfusion in cytoreductive surgery: a multivariate analysis of 243 procedures. Ann Surg Onc. 2009;16:2195-2203.
van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230-240.
Funder J, Jepsen K, Stribolt D, Iversen L. Palliative surgery for pseudomyxoma peritonei. Scand J Surg. 2016;105(2):84-89.
American College of Surgeons. National Cancer Database Participant Use File 2019. https://www.facs.org/quality-programs/cancer/ncdb/puf
National Cancer Institute Dictionary of SEER Variables. https://seer.cancer.gov/data-software/documentation/seerstat/nov2019/seerstat-variable-dictionary-nov2019.pdf